A federal panel in New York has revived litigation linking the painkiller Tylenol to autism, ruling that the trial judge wrongly excluded expert testimony before dismissing the cases. The appellate decision does not resolve liability. It returns the suits to an earlier procedural stage, now with the previously blocked testimony allowed in.
The evidentiary error behind the reversal
The federal panel's ruling turns on a single finding: the trial judge's exclusion of expert testimony did not meet the applicable standard. In product liability suits alleging that a consumer product causes a medical condition, expert witnesses typically address causation, whether the product can produce the alleged harm and whether it did so for the specific plaintiffs. Barring that testimony effectively ends the case before a jury hears any evidence. That is what happened at the trial level. The appellate panel found it was wrong.
With the exclusion reversed, the expert witnesses can now testify and the cases can proceed.
What revived litigation means for the Tylenol cases
The lawsuits allege a link between Tylenol, one of the most widely used over-the-counter painkillers in the United States, and autism. The source reporting does not identify the number of plaintiffs, the manufacturer named in the suits, the relevant trial court, or any financial exposure figures. Those details are not in the record as published.
Appellate reversal on evidentiary grounds is a procedural development, not a merits ruling. The panel has not said Tylenol causes autism. It has said the plaintiffs deserved the chance to put their science before a court.
What comes next
Further proceedings at the trial level are now required. No damages figures, settlement terms, or trial schedule have been reported.
The cases now carry the weight of an appellate court's finding that the science behind the claims was not given a fair hearing the first time.